🇺🇸 FDA

Intelligence · Clinical Pipeline

Takeda Pipeline

All ClinicalTrials.gov programs at Takeda — phase, modality, and trial IDs.

Programs
393

Quick answer

Takeda has 393 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Fosrenol (Lanthanum Carbonate)

    Takeda

    Chronic Kidney Disease, Stage 5

    phase 3 small molecule completed

    1 trial

  2. GA-GCB (velaglucerase alfa)

    Takeda

    Gaucher Disease

    phase 3 mab completed

    1 trial

  3. GLASSIA

    Takeda

    Graft Versus Host Disease

    phase 3 mab terminated

    1 trial

  4. GLASSIA

    Takeda

    Alpha1-antitrypsin Deficiency

    phase 3 mab completed

    1 trial

  5. HYQVIA

    Takeda

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy

    phase 3 mab completed

    2 trials

  6. High Dose Colchicine (4.8 mg total dose)

    Takeda

    Gout

    phase 3 small molecule completed

    1 trial

  7. Human Plasma-Derived Coagulation Factor VIII Concentrate (Virus Inactivated by Polysorbate 80 Treatment and Vapor Heat Treatment)

    Takeda

    Hemophilia A

    phase 3 small molecule completed

    1 trial

  8. HyQvia 100 mg/ml solution for infusion for subcutaneous use, HyQvia 100 mg/ml solution for infusion for subcutaneous use, TAK-881

    Takeda

    Primary Immunodeficiency Diseases

    phase 3 small molecule active

    1 trial

  9. IBI363

    Takeda

    iO Resistant sqNSCLC

    phase 3 small molecule active

    1 trial

  10. IGI, 10%

    Takeda

    Multiple Myeloma

    phase 3 mab active

    1 trial

  11. IGSC 20% infusion

    Takeda

    Primary Immunodeficiency Disease

    phase 3 mab completed

    1 trial

  12. IXAZOMIB

    Takeda

    Relapsed or Refractory Systemic Light Chain Amyloidosis

    phase 3 small molecule terminated

    1 trial

  13. Icatibant

    Takeda

    Hereditary Angioedema

    phase 3 small molecule completed

    3 trials

  14. Icatibant

    Takeda

    Angioedema

    phase 3 small molecule completed

    1 trial

  15. Icatibant

    Takeda

    Angiotensin Converting Enzyme Inhibitor Induced Angioedema

    phase 3 small molecule completed

    1 trial

  16. Iduronate-2-sulfatase enzyme replacement therapy

    Takeda

    Mucopolysaccharidosis II

    phase 3 mab completed

    1 trial

  17. Idursulfase (idursulfase-IT [HGT-2310])

    Takeda

    Hunter Syndrome and Cognitive Impairment

    phase 3 small molecule active

    1 trial

  18. Immune Globulin Infusion (Human), 10%

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  19. Immune Globulin Intravenous (Human), 10%

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 small molecule completed

    2 trials

  20. Immune Globulin Intravenous (Human), 10% (IGIV, 10%)

    Takeda

    Alzheimer´s Disease

    phase 3 small molecule terminated

    1 trial

  21. Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg

    Takeda

    Alzheimer´s Disease

    phase 3 mab completed

    1 trial

  22. Immune Globulin Intravenous (Human), 10% Solution

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  23. Immune Globulin Intravenous (Human), 10% Solution

    Takeda

    Alzheimer´s Disease

    phase 3 mab terminated

    1 trial

  24. Immune Globulin Intravenous (IGIV)

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  25. Immune Globulin Intravenous (human), 10%

    Takeda

    Multifocal Motor Neuropathy

    phase 3 mab completed

    1 trial

  26. Immune Globulin Subcutaneous (Human), 20%

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  27. Intranasal Fentanyl Spray (INFS)

    Takeda

    Break Through Pain

    phase 3 small molecule completed

    1 trial

  28. Ixazomib

    Takeda

    Relapsed Multiple Myeloma

    phase 3 small molecule completed

    1 trial

  29. Ixazomib Citrate

    Takeda

    Multiple Myeloma

    phase 3 small molecule completed

    2 trials

  30. Ixazomib, thalidomide, & dexamethasone (ITD) re-induction

    Takeda

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  31. KIOVIG 100 mg/ml solution for infusion, TECVAYLI 90 mg/mL solution for injection, TECVAYLI 10 mg/mL solution for injection, KIOVIG 100 mg/ml solution for infusion

    Takeda

    Primary infection prophylaxis for secondary immunodeficiency (SID) in patients with multiple myeloma (MM) receiving B cell maturation antigen (BCMA)-directed bispecific (BsAb) therapy

    phase 3 small molecule active

    1 trial

  32. LDX

    Takeda

    ADHD

    phase 3 small molecule completed

    1 trial

  33. LDX 30 mg

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial

  34. Lanadelumab

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    2 trials

  35. Lanadelumab

    Takeda

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  36. Lanadelumab

    Takeda

    Angioedema

    phase 3 small molecule completed

    2 trials

  37. Lansoprazole

    Takeda

    Stomach Ulcer

    phase 3 small molecule completed

    2 trials

  38. Lansoprazole and naproxen and aspirin

    Takeda

    Osteoarthritis

    phase 3 small molecule completed

    1 trial

  39. Lansoprazole microgranules suspension

    Takeda

    Gastroesophageal Reflux Disease

    phase 3 small molecule completed

    1 trial

  40. Lapaquistat Acetate

    Takeda

    Dyslipidemia

    phase 3 small molecule completed

    2 trials

  41. Lapaquistat acetate

    Takeda

    Hypercholesterolemia

    phase 3 small molecule completed

    4 trials

  42. Lapaquistat acetate and atorvastatin

    Takeda

    Hypercholesterolemia

    phase 3 small molecule completed

    2 trials

  43. Lapaquistat acetate and current lipid-lowering treatment

    Takeda

    Hypercholesterolemia

    phase 3 small molecule terminated

    1 trial

  44. Lapaquistat acetate and lipid-lowering therapy

    Takeda

    Type 2 Diabetes

    phase 3 small molecule completed

    1 trial

  45. Lapaquistat acetate and rosuvastatin

    Takeda

    Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  46. Lapaquistat acetate and simvastatin

    Takeda

    Hypercholesterolemia

    phase 3 small molecule completed

    2 trials

  47. Lapaquistat acetate and stable statin therapy

    Takeda

    Hypercholesterolemia

    phase 3 small molecule terminated

    2 trials

  48. Leuprorelin

    Takeda

    Prostate Cancer

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does Takeda have?

393 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.